Hepion pharmaceuticals highlights upcoming phase 2 clinical trials of recofilstat at 5th global nash congress

Edison, n.j., may 27, 2022 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”) and hepatocellular carcinoma (“hcc”), announces that its chief medical officer, todd hobbs, md, gave a clinical presentation entitled “recofilstat (crv431): a liver-targeting drug candidate for nash and hcc” today at the 5th global nash congress.
HEPA Ratings Summary
HEPA Quant Ranking